More recently, studies have shown that inducible elimination of glucagon action by administration of a GCGR monoclonal antibody (GCGR-Ab) enhances beta cell survival, regeneration, and function in pre-clinical models of type 1 (T1D) and type 2 (T2D) diabetes [[11], [12], [13], [14], [15], [16]]. Here, GCGR is linked to type 1 diabetes mellitus.